More than 11,000 Americans are still actively litigating claims against the makers of Nexium, Prilosec, and Prevacid — and thousands more may not yet know they qualify. The proton pump inhibitor lawsuit consolidated in federal court has become one of the most significant pharmaceutical mass torts in the country, with total settlements now exceeding half a billion dollars and a major defendant still without a global resolution. If you or someone you love took a PPI for six months or more and later developed kidney disease, what happens next in this litigation matters directly to you.
What Is MDL 2789 and Where Does It Stand in 2026?
MDL 2789, formally titled In re Proton-Pump Inhibitor Products Liability Litigation, is consolidated before Judge Claire C. Cecchi in the U.S. District Court for the District of New Jersey. The Judicial Panel on Multidistrict Litigation centralized the litigation in August 2017, beginning with 161 initial cases. What started as a relatively contained docket has grown into one of the largest active pharmaceutical MDLs in the United States.
As of May 2026, the docket reflects 18,706 total U.S. filings with 11,322 cases still active, according to the JPML’s May 1, 2026 statistics report cited by ConsumerNotice. That makes MDL 2789 the third-largest active pharmaceutical MDL in the country. The defendants named across these cases include AstraZeneca (manufacturer of Nexium and Prilosec), Takeda Pharmaceuticals (Prevacid), Pfizer and Wyeth (Protonix), and Procter & Gamble. Every major brand of prescription and over-the-counter proton pump inhibitor is represented in this litigation.
The scale of this proton pump inhibitor lawsuit reflects just how widely these medications were used. FDA data shows that approximately 21 million patients filled PPI prescriptions at U.S. outpatient retail pharmacies in a single year, making PPIs the second-largest drug class by U.S. sales. The volume of exposure — and the severity of the injuries alleged — explains why this MDL has drawn so many claimants over nearly a decade of litigation.
AstraZeneca’s $425M Settlement and the Current Payout Phase
The most significant financial development in the proton pump inhibitor lawsuit to date is AstraZeneca’s October 2023 settlement covering Nexium and Prilosec claims. Announced just days before a scheduled October 10, 2023 bellwether trial was set to begin, the deal was valued at $425 million and covered approximately 11,000 cases. As of 2026, that settlement has moved into the active claims-administration and payout phase, meaning qualifying claimants are now receiving compensation.
The timing of AstraZeneca’s settlement — on the eve of trial — underscores the litigation pressure that bellwether cases create in mass tort MDLs. When a defendant settles rather than proceed to jury verdict, it signals that the underlying liability evidence presents real risk. According to reporting by Powell & Majestro cited as of early 2026, total settlements across all defendants in this MDL now exceed half a billion dollars. For claimants whose cases were included in the AstraZeneca resolution, the focus has shifted from litigation strategy to navigating the claims-administration process and ensuring documentation is complete.
If you were injured by Nexium or Prilosec and are not yet represented, it is important to use a medical malpractice calculator as a starting point to understand the general value range of defective drug claims before consulting with qualified legal counsel about your specific situation.
Takeda Still Unresolved: What Prevacid and Protonix Claimants Face
While AstraZeneca’s portion of the litigation has reached resolution, Takeda Pharmaceuticals — the maker of Prevacid — has not finalized a global deal as of 2026. Settlement discussions have been reported, but no court-approved settlement amount exists for Takeda’s Prevacid or for Protonix claims against Pfizer and Wyeth. This leaves thousands of claimants in a state of uncertainty, unable to benefit from the momentum that resolved the AstraZeneca portion of the docket.
MDLupdate.com reported that 653 cases were resolved in 2025, representing incremental progress but not the kind of comprehensive resolution that claimants awaiting Prevacid or Protonix compensation need. The next major procedural milestone is the July 30, 2026 JPML hearing in Asheville, North Carolina, which will keep MDL 2789 in active procedural motion. Judge Cecchi’s continued oversight of the docket means case management orders, discovery obligations, and bellwether scheduling will continue to shape the litigation trajectory for Takeda claimants throughout 2026.
The unresolved status of Takeda’s cases in this proton pump inhibitor lawsuit is a reminder that mass tort MDLs rarely resolve all defendants simultaneously. Claimants with Prevacid or Protonix claims may face a longer timeline, but the underlying liability science and the precedent set by AstraZeneca’s settlement both support continued litigation pressure.
The Science: What Research Says About PPIs and Kidney Disease
The central scientific foundation of the proton pump inhibitor lawsuit comes from peer-reviewed research establishing a statistically significant link between long-term PPI use and serious kidney damage. A landmark 2016 study published in JAMA Internal Medicine (Lazarus et al., PMID 26752337) analyzed 10,482 participants in the ARIC cohort and 248,751 Geisinger Health System patients. The study found that PPI users faced a 20–50% elevated risk of chronic kidney disease compared to non-users, even after controlling for baseline health conditions.
A subsequent 2017 study found that PPI users were 98% more likely to develop kidney failure and 28% more likely to develop chronic kidney disease compared to patients who used H2 blocker medications — a class of acid reducers considered a safer alternative. These findings, combined with the CDC’s chronic kidney disease data showing how devastating CKD progression can be, formed the evidentiary backbone of plaintiffs’ claims across MDL 2789.
The injuries alleged in the proton pump inhibitor lawsuit fall into three primary categories: acute interstitial nephritis (AIN), chronic kidney disease (CKD), and end-stage renal disease (ESRD) — the most severe form, which often requires dialysis or kidney transplantation. Plaintiffs argue that manufacturers were aware of these risks but failed to disclose them to patients or to the physicians prescribing these medications. The FDA did issue drug safety communications regarding bone fracture risk in 2010 and low magnesium levels in 2011, but no adequate warning about kidney damage was ever added to PPI labeling.
MDL 2789 by the Numbers: Key Statistics at a Glance
| Metric | Data Point | Source |
|---|---|---|
| MDL Centralization Date | August 2017 | JPML Order |
| Initial Cases at Centralization | 161 cases | JPML |
| Total U.S. Filings (May 2026) | 18,706 | JPML May 1, 2026 Statistics |
| Active Cases (May 2026) | 11,322 | JPML via ConsumerNotice |
| Cases Resolved in 2025 | 653 | MDLupdate.com (Feb 2026) |
| AstraZeneca Settlement Amount | $425 million (~11,000 cases) | Powell & Majestro (April 2026) |
| Total Settlements (All Defendants) | Exceeds $500 million | Powell & Majestro (April 2026) |
| CKD Risk Elevation (JAMA 2016) | 20–50% increased risk | Lazarus et al., JAMA Internal Medicine |
| Kidney Failure Risk vs. H2 Blockers | 98% more likely | 2017 PPI Research Study |
| U.S. PPI Prescriptions (Annual) | ~21 million patients | FDA Outpatient Data |
| Next JPML Hearing | July 30, 2026 — Asheville, N.C. | JPML Schedule |
Who Qualifies for the Proton Pump Inhibitor Lawsuit in 2026?
Not every patient who took a PPI has a viable claim, but the eligibility criteria are broader than many people realize. The core requirements that legal teams evaluate when screening potential claimants in this proton pump inhibitor lawsuit include the following:
- Duration of use: Typically, six or more months of PPI use — prescription or over-the-counter — is required to establish the kind of prolonged exposure linked to kidney damage in the scientific literature.
- Documented kidney injury: Claimants must have a documented diagnosis of acute interstitial nephritis (AIN), chronic kidney disease (CKD), or end-stage renal disease (ESRD), supported by medical records including lab work showing declining kidney function.
- Timing of diagnosis: There must be a plausible temporal connection between PPI use and the onset or progression of kidney disease.
- Ruling out alternative causes: Expert medical testimony is typically required to address whether other conditions — such as diabetes, hypertension, or other nephrotoxic medications — adequately explain the kidney damage independent of PPI use.
- Specific PPI brand used: Nexium (esomeprazole), Prilosec (omeprazole), Prevacid (lansoprazole), and Protonix (pantoprazole) are the primary brands at issue. Documentation of the specific medication used, including pharmacy records or prescription history, strengthens a claim.
Understanding the general value of a potential claim is a reasonable first step. A personal injury settlement calculator can provide general context for how injury severity, duration of treatment, and economic damages factor into mass tort settlement ranges — though every individual claim requires personalized legal evaluation.
In tragic cases where kidney disease progressed to ESRD and resulted in a patient’s death, surviving family members may have standing to pursue wrongful death claims within the MDL. A wrongful death calculator can help families understand how economic and non-economic damages are typically assessed in fatal pharmaceutical cases.
What You Need to Do Right Now If You Used PPIs and Developed Kidney Disease
If you took Nexium, Prilosec, Prevacid, or Protonix for six months or more and have since been diagnosed with kidney disease, the window to act in this proton pump inhibitor lawsuit requires careful attention. Statutes of limitations vary by state, and the claims-administration phase for AstraZeneca’s settlement means that timing has already become critical for some claimants. Delays in filing can permanently bar recovery.
Your immediate steps should include gathering all relevant medical records documenting your kidney diagnosis, securing pharmacy records or prescription history showing which PPI you used and for how long, and identifying all healthcare providers who treated you for kidney-related conditions. The federal courts’ case management data confirms that MDL 2789 remains an active, evolving docket — which means claimants who have not yet filed may still have a path to recovery, particularly in the Takeda and Pfizer portions of the litigation where global resolutions have not been finalized.
Do not assume that because AstraZeneca settled, the litigation is over. With 11,322 cases still active as of May 2026 and the Takeda portion of the proton pump inhibitor lawsuit still unresolved, this MDL has substantial litigation ahead. Your circumstances, your specific PPI use, and your kidney diagnosis determine your individual claim’s viability — and that assessment begins with understanding what you took, when you took it, and what your medical records show.
Frequently Asked Questions About the Proton Pump Inhibitor Lawsuit
What kidney diseases qualify for the proton pump inhibitor lawsuit?
The primary qualifying diagnoses in MDL 2789 are acute interstitial nephritis (AIN), chronic kidney disease (CKD), and end-stage renal disease (ESRD). These conditions must be documented through medical records, including lab results showing declining kidney function such as elevated creatinine levels or reduced glomerular filtration rate (GFR). Claimants with ESRD who have required dialysis or kidney transplantation typically represent the most severe — and potentially highest-value — claims in the litigation. If your kidney disease was diagnosed after a period of sustained PPI use, your records should be reviewed by a legal professional experienced in pharmaceutical mass torts.
Did AstraZeneca’s $425M settlement resolve all PPI claims?
No. AstraZeneca’s October 2023 settlement for $425 million covered approximately 11,000 Nexium and Prilosec claims and is now in the claims-administration and payout phase as of 2026. However, Takeda Pharmaceuticals (Prevacid), Pfizer and Wyeth (Protonix), and Procter & Gamble have not finalized global settlement agreements. As of May 2026, 11,322 cases remain active in MDL 2789. Claimants with Prevacid or Protonix claims are still in active litigation, and the July 30, 2026 JPML hearing in Asheville, North Carolina is the next significant procedural milestone.
How long did I need to take a PPI to qualify for a lawsuit?
The general eligibility threshold used in the proton pump inhibitor lawsuit is six or more months of continuous or near-continuous PPI use. This criterion is grounded in the scientific research linking prolonged PPI exposure to kidney damage, including the landmark 2016 JAMA Internal Medicine study that tracked participants over extended periods of use. Shorter-term PPI use may not meet the exposure threshold needed to establish causation. Both prescription PPIs and over-the-counter versions of Nexium, Prilosec, and Prevacid are relevant — what matters is total duration of use, which pharmacy and prescription records can help document.
What is the legal theory behind PPI kidney disease claims?
The primary legal theory across MDL 2789 is failure to warn. Plaintiffs allege that pharmaceutical manufacturers including AstraZeneca, Takeda, and Pfizer knew — or should have known — about the risk of kidney damage associated with long-term PPI use and failed to disclose that risk to patients or to prescribing physicians. The FDA issued drug safety communications about PPI-related bone fracture risk in 2010 and low magnesium levels in 2011, but no kidney damage warning was ever added to PPI labeling. Plaintiffs argue that had adequate warnings been provided, patients and their doctors could have chosen alternative acid-reducing medications, such as H2 blockers, that do not carry the same kidney risk profile.
Is it too late to file a proton pump inhibitor lawsuit claim in 2026?
It depends on your state’s statute of limitations and the specific facts of your case. While AstraZeneca’s settlement is in its payout phase, the Takeda and Pfizer portions of MDL 2789 remain active, and new cases are still being filed. As of May 2026, the MDL has 11,322 active cases, confirming that the litigation is far from closed. Statutes of limitations in pharmaceutical injury cases typically run from the date of diagnosis or the date a claimant reasonably could have known about the connection between PPI use and their kidney condition — not necessarily the date they started taking the medication. The safest course of action is to have your specific situation evaluated promptly, as waiting further increases the risk of being time-barred.
This content is for informational purposes only and does not constitute legal advice or establish an attorney-client relationship.
Related reading: Medical Malpractice Expert Witness Requirements: What Every Claimant Must Know In 2026
Related reading: Pulmonology Malpractice Settlement Amounts: 2026 Data, Verdicts & How Compensation Is Calculated
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.